Table 5 Risk factors tested for association with 5-FU- and capecitabine-associated cardiotoxicity
From: Cardiotoxicity of 5-fluorouracil and capecitabine in Chinese patients: a prospective study
Variable | Patients with cardiotoxicity (n = 161) | Patients without cardiotoxicity (n = 366) | P |
|---|---|---|---|
Chemotherapy | |||
 5-Fluorouracil | 49 (30.4) | 147 (40.2) | 0.033 |
 Capecitabine | 112 (69.6) | 219 (59.8) |  |
Chemotherapy cycle | |||
 1–4 | 53 (32.9) | 143 (39.1) | 0.386 |
 5–9 | 91 (56.5) | 177 (48.4) |  |
 ≥ 9 | 9 (5.6) | 26 (7.1) |  |
 UK | 8 (5.0) | 20 (5.5) |  |
Concurrent radiotherapy | |||
 Yes | 6 (3.7) | 16 (4.4) | 0.733 |
 No | 155 (96.3) | 350 (95.6) |  |
Sex | |||
 Male | 108 (67.1) | 240 65.6) | 0.737 |
 Female | 53 (32.9) | 126 (34.4) |  |
Age, years | |||
 ≤ 29 | 4 (2.5) | 6 (1.6) | 0.257 |
 30~ | 9 (5.6) | 23 (6.3) |  |
 40~ | 33 (20.5) | 79 (21.6) |  |
 50~ | 40 (24.8) | 110 (30.1) |  |
 60~ | 54 (33.5) | 124 (33.9) |  |
 70~ | 19 (11.8) | 23 (6.3) |  |
 80~ | 2 (1.2) | 1 (0.3) |  |
Pre-existing disease | |||
 Hypertension | |||
  Yes | 44 (27.3) | 62 (16.9) | 0.006 |
  No | 117 (72.7) | 304 83.1) |  |
 Diabetes | |||
  Yes | 11 (6.8) | 18 (4.9) | 0.375 |
  No | 150 (93.2) | 348 (95.1) |  |
 Cardiac disease | |||
  Yes | 9 (5.6) | 4 (1.1) | 0.004 |
  No | 152 (94.4) | 362 (98.9) |  |
 Hyperlipidemia | |||
  Yes | 2 (1.2) | 2 (0.5) | 0.762 |
  No | 159 (98.8) | 364 (99.5) |  |
Surgical history | |||
 Yes | 129 (80.1) | 286 (78.1) | 0.608 |
 No | 32 (19.9) | 80 (21.9) |  |
Treatment history | |||
 Chemotherapy | |||
  Yes | 33 (20.5) | 85 (23.2) | 0.521 |
  No | 128 (79.5) | 281 (76.8) |  |
 Radiotherapy | |||
  Yes | 9 (5.6) | 23 (6.3) | 0.759 |
  No | 152 (94.4) | 343 (93.7) |  |
 Chemotherapy and radiotherapy | |||
  Yes | 7 (4.3) | 19 (5.2) | 0.808 |
  No | 154 (95.7) | 347 (94.8) |  |